What is the aplidin?
Aplidin (DDB) is a drug patented by PharmaMar. It is a cyclic peptide that is found in tunicates (Aplidium albicans), and is promising in the reduction of tumors in cancers of the pancreas, stomach, bladder and prostate. Presents a molecular formula is C57H87N7O15, with a molecular mass of 1110.357 g/mol. Other synonyms of aplidin are: dehydrodidemnin B and plitidepsin.
The systematic name of the IUPAC it is: (S)-N-((R)-1-(((3S,6R,7S,10R,11S,15S,17S,20S25aS)-10-((S)-sec-butil)-11-hidroxi-20-isobutil-15-isopropil-3-(4-metoxibenzil)-2,6,17-trimetil-1,4,8,13,16,18,21-heptaoxodocosahidro-1H-pyrrolo[2,1-f][1,15,4,7,10,20]dioxatetraazaciclotricosin-7-yl)amino)-4-methyl-1-oxopentane-2-yl)-N-methyl-1-(2-oxopropanoil)pirrolidine-2-carboxamide
 |
| 3D Structure |
The mechanism of action of aplidin consists in inhibition of growth and induction of apoptosis in cells MOLT-4 through indirect inhibition of VEGF secretion that blocks the loop autocrine VEGF/VEGFR-1 is required for the growth of these cells.
In addition, it presents interest as a potential treatment for some leukemias.
